10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies

The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies

The ABO blood group system, discovered by Karl Landsteiner in 1900–1901, represents the most critical antigenic system in transfusion medicine and clinical immunohematology. Unlike all other human blood group systems, ABO is the only system in which individuals predictably and consistently produce reciprocal antibodies in their plasma against the erythrocyte antigens they lack. Because anti-A and anti-B antibodies are potent complement activators capable of triggering catastrophic, life-threatening acute intravascular hemolytic transfusion reactions within minutes of incompatible red cell infusion, absolute concordance between forward (cell) and reverse (serum) grouping is an inviolable requirement before any blood component is released for transfusion.

---

1. Landsteiner's Rule and Physiological Principles

Landsteiner's rule is the foundational law of immunohematology: an individual predictably and naturally produces antibodies in their serum or plasma directed against the ABO antigens absent from their own erythrocyte membranes, provided they possess an intact, immunocompetent immune system.

                               ┌─────────────────────────────────────────────────────────┐
                               │             Landsteiner's Reciprocal Rule               │
                               └────────────────────────────┬────────────────────────────┘
                                                            │
               ┌────────────────────────────┬───────────────┴────────────┬───────────────────────────┐
               ▼                            ▼                            ▼                           ▼
        ┌──────────────┐             ┌──────────────┐             ┌──────────────┐            ┌──────────────┐
        │   Group O    │             │   Group A    │             │   Group B    │            │   Group AB   │
        └──────┬───────┘             └──────┬───────┘             └──────┬───────┘            └──────┬───────┘
               │                            │                            │                           │
        • Antigens: H only           • Antigens: A, H             • Antigens: B, H            • Antigens: A, B, H
        • Antibodies:                • Antibodies:                • Antibodies:               • Antibodies:
          Anti-A, Anti-B,              Anti-B                       Anti-A                      None
          Anti-A,B (IgG + IgM)         (predominantly IgM)          (predominantly IgM)       • Universal Recipient
        • Universal RBC Donor        • Compatible RBCs:           • Compatible RBCs:            (for RBCs)
        • Universal Plasma Recip.      A, O                         B, O                      • Universal Plasma Donor

Antibody Characteristics and Immunoglobulin Isotypes

• Isohemagglutinins (Naturally Occurring Antibodies): Production of anti-A and anti-B antibodies begins around 3 to 6 months of age, triggered by environmental exposure to ubiquitous bacterial, viral, and dietary oligosaccharides structurally identical to human ABH antigens (such as cell wall lipopolysaccharides of Escherichia coli). Antibody titers peak between 5 and 10 years of age and gradually decline in advanced senescence.
• Immunoglobulin Classes:
  • Group A and Group B Individuals: Their serum isohemagglutinins (anti-B in group A; anti-A in group B) are predominantly high-molecular-weight IgM pentamers, with minor fractions of IgG and IgA. These IgM antibodies react strongly at room temperature ($20\text{--}24^\circ\text{C}$) and below, but remain active at $37^\circ\text{C}$.
  • Group O Individuals: Their serum contains anti-A, anti-B, and a cross-reacting antibody designated anti-A,B. These antibodies are predominantly IgG (specifically subclasses $IgG_1$ and $IgG_3$), accompanied by IgM. Because monomeric IgG readily crosses the placental syncytiotrophoblast barrier via neonatal Fc receptors ($FcRn$), maternal group O women carrying group A or group B fetuses are uniquely predisposed to delivering neonates with ABO Hemolytic Disease of the Fetus and Newborn (ABO HDFN).
• Complement Activation and Intravascular Hemolysis: IgM isohemagglutinins possess a planar pentameric geometry with 10 antigen-binding Fab fragments. A single bound IgM molecule on an erythrocyte membrane can change into a "staple" conformation, exposing its $C_H3$ domains and binding the $C1q$ subunit of the classical complement cascade. Complement activation rapidly proceeds through the terminal membrane attack complex ($C5b\text{-}9$), punching lytic pores into the erythrocyte membrane and triggering massive, immediate acute intravascular hemolysis, accompanied by free hemoglobinemia, hemoglobinuria, disseminated intravascular coagulation (DIC), and acute renal failure.

---

2. Biochemical Genetics of ABH Antigens and Transferases

ABH blood group antigens are not direct gene products; instead, genes encode specific glycosyltransferase enzymes that catalyze the sequential addition of immunodominant carbohydrate residues to pre-existing carbohydrate precursor chains.

                                  ┌──────────────────────────────────────────────┐
                                  │          ABH Biosynthetic Pathway            │
                                  └──────────────────────┬───────────────────────┘
                                                         │
                                                         ▼
                                          Type 2 Precursor Oligosaccharide
                                          [Gal-beta-1,4-GlcNAc-R]
                                                         │
                                                         │ FUT1 Gene (Chromosome 19)
                                                         │ alpha-1,2-fucosyltransferase
                                                         │ (+ L-Fucose)
                                                         ▼
                                                     H Antigen
                                           [Fuc-alpha-1,2-Gal-beta-1,4-GlcNAc-R]
                                                         │
                                ┌────────────────────────┴────────────────────────┐
                                │                                                 │
                                ▼                                                 ▼
                        A Gene (Chromosome 9)                             B Gene (Chromosome 9)
                  alpha-1,3-N-acetylgalactosaminyltransferase             alpha-1,3-D-galactosyltransferase
                       (+ GalNAc)                                                (+ D-Galactose)
                                ▼                                                 ▼
                            A Antigen                                         B Antigen
                  [GalNAc-alpha-1,3-(Fuc-alpha-1,2)-Gal...]         [Gal-alpha-1,3-(Fuc-alpha-1,2)-Gal...]

The Precursor Substance and the H Gene (FUT1)

• Precursor Chains: Oligosaccharide chains terminate with $\beta$-D-galactose attached to subterminal N-acetylglucosamine. In Type 1 precursor chains (found primarily in secretory fluids and endodermally derived epithelial tissues), the terminal galactose is linked by a $\beta\text{-}1,3$ glycosidic bond to N-acetylglucosamine. In Type 2 precursor chains (found primarily on erythrocyte membranes and glycolipids/glycoproteins of mesodermal and ectodermal origin), the terminal galactose is linked by a $\beta\text{-}1,4$ glycosidic bond.
• The H Locus (FUT1): Located on chromosome $19q13.3$, the $H$ gene encodes $\alpha$-1,2-L-fucosyltransferase. This enzyme transfers an immunodominant sugar, L-fucose, from guanosine diphosphate L-fucose (GDP-Fuc) to the terminal D-galactose of Type 2 chains via an $\alpha\text{-}1,2$ linkage, producing the H antigen (H substance).
• Obligate Precursor Role: The H antigen is the mandatory substrate required by both the A and B transferases. Without H antigen synthesis, neither the A nor B transferase can attach its respective immunodominant sugar.

The ABO Locus and Immunodominant Sugars

The ABO locus, mapped to chromosome $9q34.2$, comprises seven exons and exhibits multiple functional alleles:

1. The A Gene: Encodes $\alpha$-1,3-N-acetylgalactosaminyltransferase, which transfers N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the terminal D-galactose of H substance via an $\alpha\text{-}1,3$ linkage, generating the A antigen.
2. The B Gene: Differs from the $A^1$ allele by only seven nucleotide substitutions, four of which cause critical amino acid changes ($Arg176Gly$, $Gly235Ser$, $Leu266Met$, and $Gly268Ala$) that alter the transferase donor-substrate specificity. The B gene encodes $\alpha$-1,3-D-galactosyltransferase, which transfers D-galactose from UDP-Gal to the terminal galactose of H substance via an $\alpha\text{-}1,3$ linkage, generating the B antigen.
3. The O Gene (Amorph): Contains a single critical base deletion of guanine at nucleotide position 261 ($\Delta 261$) within exon 6. This deletion induces a reading frameshift that introduces a premature translation termination codon, producing an enzymatically truncated, non-functional protein. Consequently, homozygous $OO$ individuals cannot modify H substance; their erythrocytes express abundant, unmodified H antigen.

Quantitative Hierarchy of Unmodified H Antigen Sites

Because the A and B transferases compete for and consume pre-existing H antigen sites with varying catalytic efficiencies, the density of remaining unmodified H substance on normal human red blood cells follows a strict descending hierarchy: $\mathbf{O > A_2 > B > A_2B > A_1 > A_1B}$

• Clinical Testing: The plant seed lectin extracted from Ulex europaeus serves as commercial anti-H reagent. It agglutinates group O cells with the highest intensity ($4+$) and reacts weakly or negatively with group $A_1$ and $A_1B$ cells ($0\text{ to }1+$), confirming that $A_1$ transferases consume nearly all available H chains.

---

3. The Bombay Phenotype ($O_h$, $hh$) and Secretor Genetics

                     ┌─────────────────────────────────────────────────────────┐
                     │          Bombay Phenotype (Oh / hh Genotype)            │
                     └────────────────────────────┬────────────────────────────┘
                                                  │
            ┌─────────────────────────────────────┴─────────────────────────────────────┐
            ▼                                                                           ▼
     Forward Cell Grouping                                                       Reverse Serum Grouping
  • Anti-A: 0 (Negative)                                                      • A1 Reagent Cells: 4+ Lysis/Agglutination
  • Anti-B: 0 (Negative)                                                      • B Reagent Cells:  4+ Lysis/Agglutination
  • Anti-A,B: 0 (Negative)                                                    • O Reagent Cells:  4+ Lysis/Agglutination
  • Anti-H Lectin (Ulex): 0 (Negative!)                                       • Potent, wide thermal range Anti-H
    [Mistaken for normal Group O on routine screen]                             (4°C to 37°C; violently hemolyzes O cells)

The Bombay Phenotype ($O_h$)

Discovered in 1952 by Bhende and colleagues in Bombay (now Mumbai), India, the classic Bombay phenotype is inherited as a rare autosomal recessive trait with an approximate frequency of 1 in 10,000 in India and 1 in 1,000,000 in Western populations:

• Genetics: Caused by homozygous inheritance of the silent, non-functional $h$ allele (FUT1 null, genotype $hh$). Bombay individuals completely lack $\alpha$-1,2-fucosyltransferase activity and cannot synthesize H antigen on erythrocyte Type 2 chains. Even if they possess normal $A$ or $B$ genes on chromosome 9, the A and B transferases remain inactive because their obligate acceptor substrate (H substance) is entirely absent.
• Serologic Profile:
  • Forward Grouping: Anti-A: $0$; Anti-B: $0$; Anti-A,B: $0$. The cells appear to be standard Group O.
  • Lectins: Completely negative with Ulex europaeus anti-H lectin ($0$). Normal group O cells react at $4+$.
  • Reverse Grouping: Serum strongly agglutinates $A_1$ cells ($4+$), B cells ($4+$), and all normal group O screening cells ($4+$) at room temperature and $37^\circ\text{C}$.
• The Bombay Anti-H: Normal group O individuals lack anti-H because their cells are saturated with H antigen. In contrast, Bombay ($hh$) individuals produce a potent, naturally occurring allo-anti-H. This alloantibody exhibits a wide thermal amplitude (reactive from $4^\circ\text{C}$ to $37^\circ\text{C}$), readily binds complement, and induces violent intravascular hemolysis of any transfused normal group O blood.
• Transfusion Management: Bombay individuals can receive red blood cells ONLY from other documented Bombay ($O_h$) donors. Transfusing standard group O red cells is rapidly fatal. Family pedigree screening, autologous blood pre-donation, and national/international rare donor registries are vital.

Secretor Status and the FUT2 Gene

Soluble ABH blood group substances present in body fluids (saliva, tears, gastric juice, bile, milk, and semen) are controlled by the independent $Se$ locus (FUT2) on chromosome $19q13.3$:

• Function: The $Se$ gene encodes $\alpha$-1,2-L-fucosyltransferase-2, which operates specifically on Type 1 precursor chains in secretory epithelial cells. Individuals who inherit at least one functional $Se$ allele ($SeSe$ or $Sese$, representing approximately 80% of the population) are designated Secretors. Individuals homozygous for the inactive $se$ allele ($sese$, approximately 20% of the population) are Non-Secretors.
• Antigen Expression in Secretions:

• Saliva Neutralization / Inhibition Assay: To confirm secretor status, boiled saliva (which inactivates endogenous carbohydrate-cleaving enzymes) is incubated with standardized dilutions of commercial anti-A, anti-B, or anti-H. Reagent indicator red cells are subsequently added. If soluble antigens are present in the saliva, they neutralize the antiserum, resulting in inhibition of agglutination (negative reaction indicates secretor). If no soluble antigens are present, free antiserum agglutinates the indicator cells (agglutination indicates non-secretor).

---

4. ABO Subgroups: $A_1$ vs $A_2$ and Weak Subgroups

Subgroups of group A represent inherited phenotypic variations in the quantity and structural complexity of A antigens expressed on erythrocyte membranes. The two principal subgroups are $A_1$ (accounting for approximately 80% of all group A individuals) and $A_2$ (accounting for the remaining 20%).

                                  ┌──────────────────────────────────────────────┐
                                  │        Differentiating A1 and A2 Phenotypes  │
                                  └──────────────────────┬───────────────────────┘
                                                         │
                        ┌────────────────────────────────┴────────────────────────────────┐
                        ▼                                                                 ▼
                 A1 Subgroup (80%)                                                 A2 Subgroup (20%)
  • Antigen Sites: 810,000 to 1,170,000 / RBC                      • Antigen Sites: 240,000 to 290,000 / RBC
  • Transferase: High catalytic efficiency                         • Transferase: Lower pH optimum, slower kinetics
  • Dolichos biflorus (Anti-A1 lectin): 4+                         • Dolichos biflorus (Anti-A1 lectin): 0 (Negative)
  • Anti-H Lectin (Ulex): 0 to 1+ (Weak)                           • Anti-H Lectin (Ulex): 3+ to 4+ (Strong)
  • Anti-A1 Alloantibody: Never produced                           • Anti-A1 Alloantibody: Produced by 1% to 8% of A2
                                                                     and 22% to 35% of A2B individuals

Quantitative and Qualitative Distinctions

• Quantitative: $A_1$ red blood cells express between $810,000$ and $1,170,000$ A antigen sites per erythrocyte, whereas $A_2$ red blood cells express only $240,000$ to $290,000$ sites per erythrocyte (an approximate four-fold reduction).
• Qualitative: The $A^1$ transferase operates over a broad pH range and efficiently modifies both linear and complex branched carbohydrate chains into A antigens. The $A^2$ transferase possesses a restricted, lower pH optimum and cannot efficiently glycosylate complex branched H structures, leaving substantial unmodified H antigen on the cell membrane.
• Reagent Lectins for Differentiation:
  • Dolichos biflorus (Anti-$A_1$ Lectin): Prepared from the seeds of the horse gram plant. When diluted appropriately, it specifically agglutinates $A_1$ and $A_1B$ erythrocytes ($3+\text{ to }4+$), but does NOT agglutinate $A_2$ or $A_2B$ erythrocytes ($0$).
  • Ulex europaeus (Anti-H Lectin): Agglutinates $A_2$ cells strongly ($3+\text{ to }4+$) because of high residual H antigen density, but reacts weakly or negatively with $A_1$ cells ($0\text{ to }1+$).
• The Anti-$A_1$ Alloantibody:
  • Approximately 1% to 8% of $A_2$ individuals and 22% to 35% of $A_2B$ individuals produce an unexpected allo-anti-$A_1$ in their serum.
  • Serologic Impact: When testing an $A_2$ or $A_2B$ patient, forward typing indicates group A or AB, but reverse typing with reagent $A_1$ cells displays an unexpected $1+\text{ to }2+$ agglutination reaction, creating an apparent ABO discrepancy.
  • Clinical Significance: Anti-$A_1$ is typically a benign, cold-reactive IgM antibody active only at room temperature ($20\text{--}24^\circ\text{C}$) or below, making it clinically insignificant. However, if the antibody remains active at $37^\circ\text{C}$ and reacts in the indirect antiglobulin test (IAT), it is clinically significant and capable of causing shortened erythrocyte survival; such patients must receive $A_2$ or group O red cells.

Rare Weak Subgroups of Group A

1. $A_3$: Characterized by a pathognomonic mixed-field agglutination pattern with commercial anti-A and anti-A,B reagents (small agglutinated clumps interspersed within a predominant field of unagglutinated free red blood cells). Saliva of $A_3$ secretors contains A and H substances.
2. $A_x$: Typically yields negative or barely perceptible reactions with anti-A, but agglutinates ($1+\text{ to }2+$) with polyclonal anti-A,B reagent. Their serum almost always contains clinically significant anti-$A_1$. Saliva contains only H substance (no A substance).
3. $A_{end}$: Displays very weak, mixed-field agglutination with anti-A (<10% of cells agglutinate). Secretions contain only H substance.
4. $A_{el}$: Fails to agglutinate with anti-A or anti-A,B reagents. Presence of A antigen is demonstrable solely through adsorption and heat/acid elution techniques.

---

5. Forward and Reverse Typing and ABO Discrepancies

Routine ABO grouping consists of two independent tests that must show reciprocal agreement:

• Forward (Front / Cell) Grouping: Tests patient red blood cells with commercial monoclonal antisera (Anti-A, Anti-B, and optionally Anti-A,B) to identify erythrocyte surface antigens.
• Reverse (Back / Serum) Grouping: Tests patient serum or plasma against known commercial reagent erythrocytes ($A_1$ cells and B cells) to identify expected reciprocal isohemagglutinins.

                               ┌─────────────────────────────────────────────────────────┐
                               │         Systematic ABO Discrepancy Resolution           │
                               └────────────────────────────┬────────────────────────────┘
                                                            │
         ┌──────────────────────────┬───────────────────────┴───────────────────┬──────────────────────────┐
         ▼                          ▼                                           ▼                          ▼
  ┌──────────────┐           ┌──────────────┐                            ┌──────────────┐           ┌──────────────┐
  │   Group I    │           │   Group II   │                            │  Group III   │           │   Group IV   │
  │ Antibodies   │           │   Antigens   │                            │   Proteins   │           │ Misc / Cold  │
  └──────┬───────┘           └──────┬───────┘                            └──────┬───────┘           └──────┬───────┘
         │                          │                                           │                          │
  • Newborns (<6 mo)         • A/B subgroups (A3, Ax)                    • Multiple Myeloma         • Cold auto-anti-I
  • Elderly senescence       • Leukemia / MDS                            • Waldenström's            • Cold allo (M, P1, Lea)
  • Hypogammaglobulin.       • Acquired B phenomenon                     • Rouleaux formation       • Wharton's jelly
  • Resolution:              • Resolution:                               • Resolution:              • Resolution:
    Incubate 15-30 min         Acidified anti-B (pH 6.0),                  Saline replacement         37°C prewarm, wash
    at RT or 4°C with          anti-A1 lectin, auto-serum                  technique                  cord cells, autoadsorb
    autocontrol                control, clinical review

Classification, Mechanisms, and Troubleshooting of ABO Discrepancies

An ABO discrepancy occurs whenever the results of forward grouping do not match the expected results of reverse grouping. The technologist must never release blood until the discrepancy is definitively resolved.

Group I Discrepancies (Weak or Missing Reverse Grouping Antibodies)

• Pathophysiology: Deficient or undetectable circulating isohemagglutinins in serum.
• Common Etiologies:
  1. Newborns under 4 to 6 months of age: Neonates do not synthesize their own isohemagglutinins; any ABO antibodies present are maternal IgG that crossed the placenta. For this reason, reverse typing is not valid or routinely performed on cord blood or neonates.
  2. Elderly patients: Age-related immunosenescence causes progressive decline in antibody titers.
  3. Hypogammaglobulinemia or Agammaglobulinemia: Seen in Bruton's agammaglobulinemia, Severe Combined Immunodeficiency (SCID), Common Variable Immunodeficiency (CVID), and Chronic Lymphocytic Leukemia (CLL).
  4. Immunosuppressed patients: Solid organ transplant or hematopoietic stem cell transplant recipients, chemotherapy patients, or therapeutic plasma exchange recipients.
  5. Chimerism: True genetic chimerism or artificial chimerism post-allogeneic bone marrow transplantation.
• Systematic Resolution:
  1. Review patient age, diagnosis, and medication history.
  2. Incubate the serum-cell suspension at room temperature ($20\text{--}24^\circ\text{C}$) for 15 to 30 minutes to enhance cold-reactive IgM binding.
  3. If still negative, incubate the test tubes at $4^\circ\text{C}$ for 15 to 30 minutes. Crucial Rule: When incubating at $4^\circ\text{C}$, the technologist MUST concurrently test an Autologous Control (patient cells + patient serum) and a Group O Screening Cell tube. This ensures that positive reactions represent true isohemagglutinins rather than non-specific cold autoantibodies (e.g., auto-anti-I).

Group II Discrepancies (Weak or Missing Forward Grouping Antigens)

• Pathophysiology: Weakened, blocked, or altered antigenic expression on the erythrocyte membrane.
• Common Etiologies:
  1. Subgroups of A or B: Inheritance of weak alleles ($A_3, A_x, B_3$).
  2. Hematologic Malignancies: Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelogenous leukemia (CML) can downregulate glycosyltransferase expression, yielding markedly diminished A or B antigen density.
  3. High Concentration of Soluble ABH Substances: In patients with mucin-producing adenocarcinomas (e.g., stomach or ovarian carcinoma), massive quantities of unneutralized soluble A or B substances in unwashed serum neutralize reagent anti-A or anti-B, preventing red cell agglutination.
  4. The Acquired B Phenomenon: Occurs in Group $A_1$ individuals suffering from severe lower gastrointestinal diseases (colorectal adenocarcinoma, intestinal obstruction, bowel perforation, or Escherichia coli / Proteus vulgaris septicemia). Bacterial enzymes (deacetylases) cleave the acetyl group from N-acetylgalactosamine (the Group A immunodominant sugar) on the patient's red cells, converting it into D-galactosamine. Structurally, galactosamine cross-reacts with certain monoclonal anti-B reagent clones (particularly clone ES-4), falsely typing the forward cells as Group AB while the reverse typing remains Group A (with intact anti-B in serum).
• Systematic Resolution:
  1. Wash patient erythrocytes 3 to 4 times with isotonic saline to remove excess soluble substances.
  2. To resolve Acquired B: Test patient red blood cells with acidified anti-B reagent (adjusted to pH 6.0). At pH 6.0, anti-B does NOT agglutinate acquired B cells but agglutinates true Group B cells. Concurrently, test the patient's red cells against their own autologous serum: the patient's endogenous anti-B will not agglutinate their own acquired B cells.
  3. Test with anti-A,B reagent and anti-$A_1$ lectin (Dolichos biflorus).
  4. Perform adsorption and elution studies if weak subgroups are suspected.

Group III Discrepancies (Protein Abnormalities and Rouleaux Formation)

• Pathophysiology: Hyperproteinemia causes erythrocyte stacking ("rouleaux"), mimicking macroscopic and microscopic agglutination in both forward and reverse grouping.
• Common Etiologies:
  1. Monoclonal gammopathies: Multiple Myeloma and Waldenström's Macroglobulinemia.
  2. Elevated acute-phase reactants (elevated fibrinogen) in severe sepsis or inflammation.
  3. Infusion of high-molecular-weight plasma expanders: Dextran or hydroxyethyl starch (HES).
  4. Incompletely clotted serum containing residual fibrin strands.
• Microscopic Appearance: Erythrocytes arrange in cylindrical columns resembling "stacks of coins."
• Systematic Resolution:
  • Forward grouping: Wash patient red blood cells 3 to 4 times with isotonic saline; rouleaux on forward typing is abolished because washing removes paraproteins.
  • Reverse grouping: Perform the Saline Replacement Technique:
    1. Centrifuge the serum-cell suspension showing apparent agglutination.
    2. Carefully remove the serum supernatant with a fine pipet without disturbing the cell button.
    3. Replace the removed serum with an equal volume (2 drops) of $0.9\%$ physiological saline.
    4. Gently resuspend the cell button and inspect for agglutination.
    5. Interpretation: True antigen-antibody agglutination persists following saline replacement; pseudoagglutination due to rouleaux completely disperses into a smooth, unagglutinated suspension.

Group IV Discrepancies (Miscellaneous and Polyagglutination)

• Pathophysiology: Cold-reactive antibodies, unwashed cell contaminants, or unexpected membrane modifications reacting at room temperature.
• Common Etiologies:
  1. Potent Cold Autoantibodies: High-titer auto-anti-I or auto-anti-H agglutinates all reagent cells ($A_1$, B, and autologous control) at room temperature.
  2. Cold Alloantibodies: Clinically benign alloantibodies such as anti-M, anti-$P_1$, or anti-$Le^a$ present in patient serum reacting with corresponding antigens present on commercial $A_1$ or B reagent red cells.
  3. Wharton's Jelly Contamination: Umbilical cord blood samples collected from the placenta are frequently contaminated with viscous hyaluronic acid-rich Wharton's jelly, causing non-specific agglutination in all forward typing tubes.
  4. Polyagglutinable Red Blood Cells (T-activation): Bacterial neuraminidase cleave terminal sialic acid residues, exposing hidden cryptantigens (Thomsen-Friedenreich / T antigen). Because all adult human sera contain naturally occurring anti-T, these T-activated cells are agglutinated by virtually all human reagents.
• Systematic Resolution:
  • For Cold Autoantibodies: Perform the $37^\circ\text{C}$ Prewarming Technique: Prewarm patient serum and reagent red cells separately to $37^\circ\text{C}$ for 10 minutes, mix while maintaining $37^\circ\text{C}$, centrifuge at $37^\circ\text{C}$, and read immediately. Alternatively, perform cold autologous adsorption (adsorb serum with patient's own enzyme-treated cells at $4^\circ\text{C}$ to remove auto-anti-I).
  • For Cold Alloantibodies: Perform an unexpected antibody screen; if anti-M is identified, repeat reverse typing using $A_1$ and B reagent cells documented to be antigen-negative (e.g., M-negative $A_1$ cells).
  • For Wharton's Jelly: Wash cord blood erythrocytes 6 to 8 times with warm ($37^\circ\text{C}$) physiological saline before forward testing; obtain a fresh non-cord heelstick sample if contamination persists.

---

6. ABO Discrepancy Classification and Troubleshooting Reference Table